StreetInsider.com News Articles

Form 6-K Cardiol Therapeutics For: Sep 10

Fri, 11 Sep 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260911/27050433.html

Form 6-K Cardiol Therapeutics For: Sep 10

Thu, 10 Sep 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260910/27049356.html

Cardiol Therapeutics files $150M shelf prospectus after OSC review

Thu, 10 Sep 2026 17:00:57 -0400

Cardiol Therapeutics Inc. (NASDAQ: CRDL) has filed a preliminary short form base shelf prospectus with Canadian securities regulators and a corresponding registration statement on Form F-10 with the U.S. Securities and Exchange Commission, the company announced Sept. 10, 2026.

The filing would allow Cardiol to offer and sell up to $150 million in securities over a 25-month period once the final prospectus receives a receipt and the registration statement becomes effective. Securities could include Class A common shares, debt securities, warrants, subscription receipts, units, or combinations thereof. No securities are currently being offered, and the filing does not obligate the company

Cardiol Therapeutics files $150M shelf prospectus after OSC review

Thu, 10 Sep 2026 17:00:57 -0400

Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission

Thu, 10 Sep 2026 17:00:00 -0400

TORONTO, Sept. 10, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has filed a preliminary short form base shelf prospectus (the "Shelf Prospectus") with the securities regulatory authorities in each of the provinces and territories of Canada, together with a corresponding registration statement on Form F-10 (the "Registration Statement") with the United States Securities and Exchange Commission (the "SEC") under the U.S./Canada

Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission

Thu, 10 Sep 2026 17:00:00 -0400

Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission

Thu, 10 Sep 2026 17:00:00 -0400

Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission

Thu, 10 Sep 2026 17:00:00 -0400

Form F-X Cardiol Therapeutics Filed by: Cardiol Therapeutics Inc.

Thu, 10 Sep 2026 13:54:00 -0400

si-local-file:///var/storage/secattach/20260910/27047711.html

Cardiol Therapeutics (CRDL) files $150M mixed shelf

Thu, 10 Sep 2026 12:46:58 -0400

Cardiol Therapeutics (NASDAQ: CRDL) filed $150,000,000 mixed shelf of:

Common Shares
Debt Securities
Warrants
Subscription Receipts
Units

Cardiol Therapeutics (CRDL) files $150M mixed shelf

Thu, 10 Sep 2026 12:46:58 -0400

Cardiol Therapeutics (NASDAQ: CRDL) filed $150,000,000 mixed shelf of:

Common Shares
Debt Securities
Warrants
Subscription Receipts
Units

Form F-10 Cardiol Therapeutics

Thu, 10 Sep 2026 12:45:00 -0400

si-local-file:///var/storage/secattach/20260910/27047448.html

Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference

Wed, 09 Sep 2026 07:27:00 -0400

TORONTO, Sept. 9, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the H.C. Wainwright 28^th Annual Global Investment Conference in New York, NY, on September 14, 2026, at 10:30 a.m. EDT.

Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference

Wed, 09 Sep 2026 07:27:00 -0400

B.Riley Starts Cardiol Therapeutics (CRDL) at Buy

Wed, 26 Aug 2026 02:11:14 -0400

B.Riley analyst Mayank Mamtani initiates coverage on Cardiol Therapeutics (NASDAQ: CRDL) with a Buy rating and a price target of $11.00.

The analyst comments: “We are initiating coverage of cardiac inflammation specialist Cardiol Therapeutics Inc. (CRDL) with a Buy rating and a 12-month price target of $11/share. We view CRDL's lead candidate, CardiolRx, as significantly de-risked in the ongoing pivotal Ph3 MAVERIC trial, with top-line data expected in 1Q27E, to become the first oral maintenance therapy in recurrent pericarditis (RP), i.e., relapsing inflammation of the sac surrounding the heart. CardiolRx targets the core RP disease etiology, a self amplifying interleukin-1 (IL-1)

B.Riley Starts Cardiol Therapeutics (CRDL) at Buy

Wed, 26 Aug 2026 02:11:14 -0400

B.Riley analyst Mayank Mamtani initiates coverage on Cardiol Therapeutics (NASDAQ: CRDL) with a Buy rating and a price target of $11.00.

Cardiol Therapeutics (CRDL) PT Raised to $10 at Canaccord

Mon, 17 Aug 2026 06:58:38 -0400

Canaccord analyst Edward Nash raised the price target on Cardiol Therapeutics (NASDAQ: CRDL) to $10.00 (from $8.00) while maintaining a Buy rating.

Form SCHEDULE 13G/A Cardiol Therapeutics Filed by: MMCAP International Inc. SPC

Fri, 14 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260814/26930528.html

Form SCHEDULE 13G/A Cardiol Therapeutics Filed by: MMCAP International Inc. SPC

Fri, 14 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260814/26930528.html

Form 6-K Cardiol Therapeutics For: Jun 30

Wed, 12 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260812/26913015.html

Form 6-K Cardiol Therapeutics For: Jun 30

Wed, 12 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260812/26913015.html

Form 6-K Cardiol Therapeutics For: Aug 05

Wed, 05 Aug 2026 07:38:00 -0400

si-local-file:///var/storage/secattach/20260805/26870364.html

Form 6-K Cardiol Therapeutics For: Aug 05

Wed, 05 Aug 2026 07:38:00 -0400

si-local-file:///var/storage/secattach/20260805/26870364.html

Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference

Wed, 05 Aug 2026 07:27:00 -0400

TORONTO, Aug. 5, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference in Boston, MA, on August 11, 2026, at 9:00 a.m. EDT.

Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference

Wed, 05 Aug 2026 07:27:00 -0400